IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada ...

Health Canada's approval is based on data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults aged 60 years and older in 22 countries. No serious safety ...

ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada ...

Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack ...

The safety and efficacy data in CABG patients from STAR-T form the basis of our marketing approval submissions. The Health Canada Medical Device License (MDL) authorizes manufacturers to import or ...

The safety and efficacy data in CABG patients from STAR-T form the basis of our marketing approval submissions. The Health Canada Medical Device License (MDL) authorizes manufacturers to import or ...

"It's like pesticides have constitutional rights and they are innocent until proven guilty," said Elizabeth May, the federal ...

Atopic dermatitis (AD), an inflammatory skin condition, is the most common form of eczema and is estimated ... to significant emotional and mental health challenges. A topical JAK inhibitor ...

Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good morning and welcome to Ocugen’s Third Quarter 2024 Financial ...

Operator Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator ...

More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and ...

Atopic dermatitis (AD), an inflammatory skin condition, is the most common form of eczema and is estimated to impact ... Not surprisingly, atopic dermatitis can lead to significant emotional and ...